Referencing for people who value simplicity, privacy, and speed.Get Citationsy
← Back to Search
The Pharmacology And Mechanism Of Action Of Riluzole
Published 1996 · Chemistry, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
The excitotoxic hypothesis of neurodegeneration has stimulated much interest in the possibility of using compounds that will block excitotoxic processes to treat neurologic disorders.Riluzole is a neuroprotective drug that blocks glutamatergic neurotransmission in the CNS. Riluzole inhibits the release of glutamic acid from cultured neurons, from brain slices, and from corticostriatal neurons in vivo. It is thought these effects may be partly due to inactivation of voltage-dependent sodium channels on glutamatergic nerve terminals, as well as activation of a G-protein-dependent signal transduction process. Riluzole also blocks some of the postsynaptic effects of glutamic acid by noncompetitive blockade of N-methyl-D-aspartate (NMDA) receptors. In vivo, riluzole has neuroprotective, anticonvulsant, and sedative properties. In a rodent model of transient global cerebral ischemia, a complete suppression of the ischemia-evoked surge in glutamic acid release has been observed. In vitro, riluzole protects cultured neurons from anoxic damage, from the toxic effects of glutamic-acid-uptake inhibitors, and from the toxic factor in the CSF of patients with amyotrophic lateral sclerosis. NEUROLOGY 1996;47(Suppl 4): S233-S241
This paper references
Disability care and education in 19th century India: some dates, places and documentation.
M. Miles (1994)
Neuroprotective effects of riluzole in ALS CSF toxicity.
P. Couratier (1994)
Methamphetamine and dopamine neurotoxicity: differential effects of agents interfering with glutamatergic transmission
A. Boireau (1995)
Neuroprotective actions of riluzole in rodent models of global and focal ischaemia
J Pratt (1992)
Neuroprotective effects of riluzole on a model of parkinson's disease in the rat
P. Barnéoud (1996)
Excitatory amino acid transmitters.
J. Watkins (1981)
Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.
A. Boireau (1994)
2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission—I: Anticonvulsant properties
J. Mizoule (1985)
Is the adipocyte β-adrenoceptor a prototype for the recently cloned atypical ‘β3-adrenoceptor?’
J. Zaagsma (1990)
Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action
J. P. Hubert (1994)
Riluzole and experimental parkinsonism: partial antagonism of MPP+-induced increase in striatal extracellular dopamine in rats in vivo
A. Boireau (1994)
Differential pharmacology of cloned human and mouse B2 bradykinin receptors.
J. Hess (1994)
Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole.
T. Hébert (1994)
Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study.
A. Benazzouz (1995)
Excitatory amino acid neurotoxicits and neurodegenerative disease
B Meldrum (1990)
Neuroprotective effects of riluzole on N-methyl-d-aspartate- or veratridine-induced neurotoxicity in rat hippocampal slices
C. Malgouris (1994)
Glutamate Receptors of a Quisqualate‐Kainate Subtype are Involved in the Presynaptic Regulation of Dopamine Release in the Cat Caudate Nucleus in vivo
L. Barbeito (1990)
Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes.
M. Debono (1993)
Protective effect of riluzole on excitatory amino acid-mediated neurotoxicity in motoneuron-enriched cultures.
A. Estevez (1995)
Neuroprotective Strategies in a Model of Chronic Glutamate‐Mediated Motor Neuron Toxicity
J. Rothstein (1995)
Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo
A. Chéramy (1992)
Information management challenges.
Bleich Mr (1990)
[Pace of demographic transition and age structure change in Korea].
Y. Han (1989)
Effect of riluzole on focal cerebral ischemia in rats.
F. Wahl (1993)
2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission—II: Biochemical properties
J. Benavides (1985)
Excitatory amino acids as a final common pathway for neurologic disorders.
S. Lipton (1994)
Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischemic gerbils
C. Malgouris (1989)
Advances in amyotrophic lateral sclerosis
O. Hardiman (1996)
Riluzole prevents anoxic injury in cultured cerebellar granule neurons.
F. Dessì (1993)
Pertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on aspartate art ate release from cerebellar granule cells
Cell culture evidence for neuronal degeneration in amyotrophic lateral sclerosis being linked to glutamate AMPA/kainate receptors
P. Couratier (1993)
a possible antagonist of excitatory amino acid neurotransmission. I
J Benavides (1985)
The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1.
D. Martin (1993)
Effect of H1 blockers alone and in combination with morphine to produce antinociception in mice
C. J. Sun (1985)
This paper is referenced by
Targeting glial physiology and glutamate cycling in the treatment of depression.
Gerald W Valentine (2009)
ALS: A Disease of Motor Neurons and Their Nonneuronal Neighbors
S. Boillée (2006)
Riluzole Can Improve Sensory and Motor Function in Patients with Acute Spinal Cord Injury
A. Meshkini (2018)
C. D. Del Negro (2018)
Predicting prognosis after stroke
M. Frankel (2000)
Riluzole attenuates the effects of chemoconvulsants acting on glutamatergic and GABAergic neurotransmission in the planarian Dugesia tigrina.
L. Ramakrishnan (2013)
Targeting the Glutamatergic System to Treat Major Depressive Disorder
D. Mathews (2012)
Using genetically modified stem cells to halt the progression of ALS
Francisco D. Benavides (2013)
Involvement of extrasynaptic glutamate in physiological and pathophysiological changes of neuronal excitability
B. Pál (2018)
Contribution of persistent sodium currents to the excitability of tonic firing substantia gelatinosa neurons of the rat
Jin-Hwa Cho (2015)
Antagonists and agonists at the glycine site of the NMDA receptor for therapeutic interventions.
M. Jansen (2003)
Pathological correlations between traumatic brain injury and chronic neurodegenerative diseases
Marcela Cruz-Haces (2017)
The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK.
F. Duprat (2000)
NMDA and AMPA/kainate receptors are involved in the anticonvulsant activity of riluzole in DBA/2 mice.
G. De Sarro (2000)
Involvement of ion channels in ischemia-induced taurine release in the mouse hippocampus.
P. Saransaari (2000)
Sodium channels and therapy of central nervous system diseases.
C. Taylor (1997)
The effects of riluzole on neurological, brain biochemical, and histological changes in early and late term of sepsis in rats.
H. Toklu (2009)
Effects of riluzole on electrically evoked neurotransmitter release
T. Jehle (2000)
Unsolved Medical Problems: Blood-brain barrier in neurodegenerative diseases: perspectives for Nanomedicine
S. Süssmuth (2009)
Characterization of the role of corticotropin-releasing hormone and opioid peptides on hippocampal neurodegeneration and functional recovery following global cerebral ischemia in rats
C. Charron (2007)
Riluzole prevents ischemic spinal cord injury caused by aortic crossclamping.
L. Lang-Lazdunski (1999)
A pharmaco-metabolomics approach in a clinical trial of ALS: Identification of predictive markers of progression
H. Blasco (2018)
Functional Multipotency of Stem Cells: A Conceptual Review of Neurotrophic Factor-Based Evidence and Its Role in Translational Research
Y. Teng (2011)
Natural History of Amyotrophic Lateral Sclerosis
M. J. Magnussen (2017)
Role of Sodium Channels in Epilepsy.
David I Kaplan (2016)
Protective effect of combination of sulforaphane and riluzole on glutamate-mediated excitotoxicity.
Geng Chang (2010)
Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date
L. Fung (2015)
Assessing Effects of BHV-0223 40 mg Zydis Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym
Diane M. Longo (2020)
Sub-cellular localization and regulatory mechanisms of AMPA receptors in motor neurons of a murine model of familial Amyotrophic Lateral Sclerosis
Peitro Veglianese (2007)
Advances in the treatment of anxiety: Targeting glutamate
A. Simon (2011)
p38 MAP kinase-mediated NMDA receptor-dependent suppression of hippocampal hypersynchronicity in a mouse model of Alzheimer’s disease
Arne Ittner (2014)
Riluzole as an Adjunctive Therapy to Risperidone for the Treatment of Irritability in Children with Autistic Disorder: A Double-Blind, Placebo-Controlled, Randomized Trial
A. Ghaleiha (2013)See more